{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:17:28Z","timestamp":1788337048743,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10620-024-08792-0","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T08:01:03Z","timestamp":1734681663000},"page":"469-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD"],"prefix":"10.1007","volume":"70","author":[{"given":"Kush","family":"Fansiwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny S.","family":"Sauk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"8792_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. The lancet 2021;398:803\u2013816.","journal-title":"The lancet"},{"key":"8792_CR2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature reviews Drug discovery. 2017;16:843\u2013862.","journal-title":"Nature reviews Drug discovery."},{"key":"8792_CR3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","volume":"118","author":"HM Hammaren","year":"2019","unstructured":"Hammaren HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine 2019;118:48\u201363.","journal-title":"Cytokine"},{"key":"8792_CR4","doi-asserted-by":"crossref","first-page":"106362","DOI":"10.1016\/j.phrs.2022.106362","volume":"183","author":"R Roskoski Jr","year":"2022","unstructured":"Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacol Res 2022;183:106362.","journal-title":"Pharmacol Res"},{"key":"8792_CR5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","volume":"17","author":"A Salas","year":"2020","unstructured":"Salas A, Hernandez-Rocha C, Duijvestein M et al. JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease. Nature reviews Gastroenterology Hepatology. 2020;17:323\u2013337.","journal-title":"Nature reviews Gastroenterology Hepatology."},{"key":"8792_CR6","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/jcm12227132","volume":"12","author":"T Deyhim","year":"2023","unstructured":"Deyhim T, Cheifetz AS, Papamichael K. Drug clearance in patients with inflammatory bowel disease treated with biologics. Journal of Clinical Medicine 2023;12:7132.","journal-title":"Journal of Clinical Medicine"},{"key":"8792_CR7","doi-asserted-by":"crossref","first-page":"897936","DOI":"10.3389\/fmed.2022.897936","volume":"9","author":"J Marsal","year":"2022","unstructured":"Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease. Frontiers in Medicine. 2022;9:897936.","journal-title":"Frontiers in Medicine."},{"key":"8792_CR8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","volume":"9","author":"N Chanchlani","year":"2024","unstructured":"Chanchlani N, Lin S, Bewshea C et al. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study. The Lancet Gastroenterology & Hepatology 2024;9:521\u2013538.","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"8792_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08791-1","author":"JD Kaunitz","year":"2024","unstructured":"Kaunitz JD. Sometimes small is beautiful: discovery of theJanus kinases (JAK) and signal transducer and activator of transcription (STAT) pathways and the initial development of JAKinhibitors for IBD treatment. Digestive Diseases and Sciences. 2024. https:\/\/doi.org\/10.1007\/s10620-024-08791-1","journal-title":"Digestive Diseases and Sciences"},{"key":"8792_CR10","doi-asserted-by":"crossref","first-page":"1089099","DOI":"10.3389\/fmed.2023.1089099","volume":"10","author":"C Herrera-deGuise","year":"2023","unstructured":"Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: a new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne) 2023;10:1089099.","journal-title":"Front Med (Lausanne)"},{"key":"8792_CR11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u20131736.","journal-title":"N Engl J Med."},{"key":"8792_CR12","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/apt.16626","volume":"54","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Khanna R, Sandborn WJ et al. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther 2021;54:1442\u20131453.","journal-title":"Aliment Pharmacol Ther"},{"key":"8792_CR13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.01.029","volume":"12","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Ghosh S, Panes J et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12:e1482.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8792_CR14","first-page":"e2111","volume":"19","author":"JA Berinstein","year":"2021","unstructured":"Berinstein JA, Sheehan JL, Dias M et al. Tofacitinib for Biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol. 2021;19:e2111.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8792_CR15","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","volume":"119","author":"A Singh","year":"2024","unstructured":"Singh A, Goyal MK, Midha V et al. Tofacitinib in acute severe ulcerative colitis (tacos): a randomized controlled trial. Am J Gastroenterol 2024;119:1365\u20131372.","journal-title":"Am J Gastroenterol"},{"key":"8792_CR16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1443-1661.2009.00916.x","volume":"22","author":"F Hirai","year":"2010","unstructured":"Hirai F, Matsui T, Aoyagi K et al. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc 2010;22:39\u201344.","journal-title":"Dig Endosc"},{"key":"8792_CR17","doi-asserted-by":"crossref","first-page":"i156","DOI":"10.1093\/ecco-jcc\/jjad212.0086","volume":"18","author":"N Narula","year":"2024","unstructured":"Narula N, Peerani F, Hansen T et al. DOP46 Tofacitinib for hospitalized acute severe ulcerative colitis\u2013the TRIUMPH study. Journal of Crohn\u2019s and Colitis. 2024;18:i156\u2013i156.","journal-title":"Journal of Crohn's and Colitis."},{"key":"8792_CR18","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. The Lancet 2021;397:2372\u20132384.","journal-title":"The Lancet"},{"key":"8792_CR19","unstructured":"Insights on Filgotinib in Crohn's Disease From the DIVERSITY1 and SELECTION Studies. Gastroenterol Hepatol (N Y). 2023 , 19:21\u201322."},{"key":"8792_CR20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. The lancet. 2022;399:2113\u20132128.","journal-title":"The lancet."},{"key":"8792_CR21","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP et al. Upadacitinib induction and maintenance therapy for Crohn\u2019s disease. New England Journal of Medicine. 2023;388:1966\u20131980.","journal-title":"New England Journal of Medicine."},{"key":"8792_CR22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1759720X17706454","volume":"9","author":"V Rios Rodriguez","year":"2017","unstructured":"Rios Rodriguez V, Poddubnyy D. Tumor necrosis factor-\u03b1 (TNF\u03b1) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy. Therapeutic Advances in Musculoskeletal Disease. 2017;9:197\u2013210.","journal-title":"Therapeutic Advances in Musculoskeletal Disease."},{"key":"8792_CR23","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song I-H, Pangan AL et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. The Lancet 2019;394:2108\u20132117.","journal-title":"The Lancet"},{"key":"8792_CR24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, Van den Bosch F, Poddubnyy D et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2022;400:369\u2013379.","journal-title":"The Lancet"},{"key":"8792_CR25","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370:2377\u20132386.","journal-title":"New England Journal of Medicine."},{"key":"8792_CR26","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New England Journal of Medicine. 2012;367:495\u2013507.","journal-title":"New England Journal of Medicine."},{"key":"8792_CR27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. The Lancet 2017;390:457\u2013468.","journal-title":"The Lancet"},{"key":"8792_CR28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet 2013;381:451\u2013460.","journal-title":"The Lancet"},{"key":"8792_CR29","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis & Rheumatology. 2017;69:506\u2013517.","journal-title":"Arthritis & Rheumatology."},{"key":"8792_CR30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen Y-C et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Annals of the Rheumatic Diseases 2017;76:88\u201395.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"8792_CR31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, Van Der Heijde D et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. New England Journal of Medicine. 2017;376:652\u2013662.","journal-title":"New England Journal of Medicine."},{"key":"8792_CR32","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O et al. Baricitinib in patients with refractory rheumatoid arthritis. New England Journal of Medicine. 2016;374:1243\u20131252.","journal-title":"New England Journal of Medicine."},{"key":"8792_CR33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O et al. Two phase 3 trials of baricitinib for alopecia areata. New England Journal of Medicine 2022;386:1687\u20131699.","journal-title":"New England Journal of Medicine"},{"key":"8792_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.07.033","author":"M Shehab","year":"2024","unstructured":"Shehab M, Alrashed F, Alsayegh A et al. Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis. Clinical Gastroenterology and Hepatology. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.033.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8792_CR35","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","volume":"360","author":"R Panaccione","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: an indirect treatment comparison using Bayesian network meta-analysis. Crohn\u2019s & Colitis 2023;360:otad009.","journal-title":"Crohn\u2019s & Colitis"},{"key":"8792_CR36","first-page":"14309","volume":"123","author":"D Ahuja","year":"2022","unstructured":"Ahuja D, Murad MH, Ma C, Jairath V, Singh S. Comparative speed of early symptomatic remission with advanced therapies for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Official journal of the American College of Gastroenterology ACG. 2022;123:14309.","journal-title":"Official journal of the American College of Gastroenterology ACG."},{"key":"8792_CR37","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","volume":"17","author":"JP Gisbert","year":"2023","unstructured":"Gisbert JP, Garc\u00eda MJ, Chaparro M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. Journal of Crohn\u2019s and Colitis 2023;17:972\u2013994.","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"8792_CR38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","volume":"72","author":"B Barberio","year":"2023","unstructured":"Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn\u2019s disease: systematic review and network meta-analysis. Gut 2023;72:264\u2013274.","journal-title":"Gut"},{"key":"8792_CR39","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1016\/j.cgh.2023.12.023","volume":"22","author":"SK Vuyyuru","year":"2024","unstructured":"Vuyyuru SK, Nguyen TM, Murad MH et al. Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn\u2019s disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2024;22:e1115.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8792_CR40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/apt.18110","volume":"60","author":"M Attauabi","year":"2024","unstructured":"Attauabi M, Steenholdt C, Poulsen A et al. Network meta-analysis: comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn\u2019s disease. Aliment Pharmacol Ther 2024;60:124\u2013143.","journal-title":"Aliment Pharmacol Ther"},{"key":"8792_CR41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u2013326.","journal-title":"N Engl J Med."},{"key":"8792_CR42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82:119\u2013129.","journal-title":"Ann Rheum Dis."},{"key":"8792_CR43","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","volume":"82","author":"MD Russell","year":"2023","unstructured":"Russell MD, Stovin C, Alveyn E et al. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Annals of the Rheumatic Diseases 2023;82:1059\u20131067.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"8792_CR44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","volume":"17","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, D\u2019Haens GR, Sands BE et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme. Journal Crohns Colitis 2023;17:338\u2013351.","journal-title":"Journal Crohns Colitis"},{"key":"8792_CR45","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/ecco-jcc\/jjac190.0035","volume":"17","author":"B Feagan","year":"2023","unstructured":"Feagan B, Matsuoka K, Rogler G et al. OP35 efficacy and safety outcomes up to~ 4 years of treatment with Filgotinib 200 mg among patients with ulcerative colitis: results from the SELECTIONLTE study. Journal of Crohn\u2019s and Colitis 2023;17:i47\u2013i50.","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"8792_CR46","doi-asserted-by":"crossref","first-page":"e1512","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 2020;158:e1512.","journal-title":"Gastroenterology"},{"key":"8792_CR47","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00011-023-01789-x","volume":"72","author":"C Sun","year":"2023","unstructured":"Sun C, Su Z, Zeng Y-P. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis. Inflammation Research 2023;72:1861\u20131871.","journal-title":"Inflammation Research"},{"key":"8792_CR48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/ibd\/izz037","volume":"25","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Inflammatory Bowel Diseases 2019;25:627\u2013641.","journal-title":"Inflammatory Bowel Diseases"},{"key":"8792_CR49","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.14309\/00000434-201710001-00740","volume":"112","author":"U Mahadevan","year":"2017","unstructured":"Mahadevan U, Baumgart DC, Dubinsky MC et al. Pregnancy outcomes in the tofacitinib ulcerative colitis OCTAVE studies: 740. Official journal of the American College of Gastroenterology ACG 2017;112:S410\u2013S411.","journal-title":"Official journal of the American College of Gastroenterology ACG"},{"key":"8792_CR50","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","volume":"47","author":"U Mahadevan","year":"2024","unstructured":"Mahadevan U, Levy G, Gensler L et al. Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports. Drug Safety 2024;47:1039\u20131049.","journal-title":"Drug Safety"},{"key":"8792_CR51","doi-asserted-by":"crossref","first-page":"otab030","DOI":"10.1093\/crocol\/otab030","volume":"3","author":"EM Llano","year":"2021","unstructured":"Llano EM, Shrestha S, Burstein E, Boktor M, Fudman DI. Favorable outcomes combining vedolizumab with other biologics or tofacitinib for treatment of inflammatory bowel disease. Crohns Colitis 360 2021;3:otab030.","journal-title":"Crohns Colitis 360"},{"key":"8792_CR52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10620-023-08182-y","volume":"69","author":"Y Miyatani","year":"2024","unstructured":"Miyatani Y, Choi D, Choi NK, Rubin DT. Dual-targeted therapy with upadacitinib and ustekinumab in medically complex Crohn\u2019s disease. Digestive Diseases and Sciences 2024;69:355\u2013359.","journal-title":"Digestive Diseases and Sciences"},{"key":"8792_CR53","doi-asserted-by":"crossref","first-page":"i091","DOI":"10.1093\/ecco-jcc\/jjab232.081","volume":"16","author":"S Danese","year":"2022","unstructured":"Danese S, Panaccione R, D\u2019Haens G et al. DOP42 efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study. Journal of Crohn\u2019s and Colitis 2022;16:i091\u2013i092.","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"8792_CR54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40265-023-01882-9","volume":"83","author":"SK Vuyyuru","year":"2023","unstructured":"Vuyyuru SK, Shackelton LM, Hanzel J, Ma C, Jairath V, Feagan BG. Targeting IL-23 for IBD: rationale and progress to date. Drugs 2023;83:873\u2013891.","journal-title":"Drugs"},{"key":"8792_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.08.032","author":"JF Colombel","year":"2024","unstructured":"Colombel JF, Lacerda AP, Irving PM et al. Efficacy and safety of upadacitinib for perianal fistulizing crohn\u2019s disease: a post hoc analysis of 3 phase 3 Trials. Clin Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.08.032.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-024-08792-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-024-08792-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:41:19Z","timestamp":1739972479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-024-08792-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["8792"],"URL":"https:\/\/doi.org\/10.1007\/s10620-024-08792-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}